Lymphoblastic lymphoma

Summary

Lymphoblastic lymphoma (MONDO:0000873) is a cancer and 91 clinical trials. Top therapeutic interventions include daunorubicin, mercaptopurine anhydrous, and pegaspargase. A subtype of precursor lymphoblastic lymphoma/leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 91

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lymphoblastic lymphoma
Mondo ID	MONDO:0000873
DOID	DOID:0080147
NCIT	C9360
SNOMED CT	109965004
UMLS	C0079748
MedGen	42541
GARD	0003329
Is cancer (heuristic)	yes

Also known as: lymphoblastic lymphoma · lymphoma, lymphoblastic · lymphoma, lymphoblastic, malignant · precursor cell lymphoblastic lymphoma · precursor lymphoblastic lymphoma

Data availability: 3 cell lines.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › lymphoblastic lymphoma

Related subtypes (3): T lymphoblastic leukemia/lymphoma, acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality

Subtypes (2): T-cell childhood lymphoblastic lymphoma, T-lymphoblastic lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 91.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	32
Not specified	24
PHASE1	14
PHASE1/PHASE2	10
PHASE4	4
PHASE3	3
PHASE2/PHASE3	2
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06289673	PHASE4	RECRUITING	Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
NCT00199017	PHASE4	COMPLETED	German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
NCT00199082	PHASE4	COMPLETED	Newly Diagnosed Mature B-ALL, Burkitt’s Lymphoma and Other High-grade Lymphoma in Adults
NCT02938741	PHASE4	UNKNOWN	ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors
NCT02845882	PHASE3	ACTIVE_NOT_RECRUITING	LBL-2016 for Children or Adolescents in China
NCT03117751	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT05602194	PHASE3	ACTIVE_NOT_RECRUITING	Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT02881086	PHASE3	COMPLETED	Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
NCT03564704	PHASE2/PHASE3	UNKNOWN	Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
NCT01574274	PHASE2	ACTIVE_NOT_RECRUITING	SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
NCT02506933	PHASE2	ACTIVE_NOT_RECRUITING	Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
NCT03136146	PHASE2	RECRUITING	Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
NCT03314974	PHASE2	RECRUITING	Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03779854	PHASE2	RECRUITING	Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT04060277	PHASE2	ACTIVE_NOT_RECRUITING	Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
NCT04195633	PHASE2	RECRUITING	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
NCT05735717	PHASE2	RECRUITING	MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
NCT05885464	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
NCT06207123	PHASE1/PHASE2	RECRUITING	A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
NCT06364423	PHASE1/PHASE2	RECRUITING	Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
NCT06477549	PHASE2	RECRUITING	BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
NCT06508099	PHASE2	RECRUITING	Vitamin A and D Supplementation in Allogeneic HCT
NCT06514794	PHASE2	RECRUITING	A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
NCT06533748	PHASE2	RECRUITING	Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
NCT06918431	PHASE2	RECRUITING	Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT07070219	PHASE1/PHASE2	RECRUITING	A Study of CTD402 in T-ALL/LBL Patients
NCT07224100	PHASE2	RECRUITING	Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
NCT00186875	PHASE2	COMPLETED	Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00195871	PHASE2	UNKNOWN	Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma
NCT00199030	PHASE2	COMPLETED	Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath
NCT00412243	PHASE1/PHASE2	COMPLETED	Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
NCT00587054	PHASE2	COMPLETED	Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
NCT00719888	PHASE2	COMPLETED	Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
NCT00866749	PHASE2	COMPLETED	Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
NCT01163201	PHASE1/PHASE2	WITHDRAWN	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
NCT01363128	PHASE2	COMPLETED	Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT01451515	PHASE2	COMPLETED	NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
NCT01474681	PHASE1/PHASE2	COMPLETED	Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
NCT01513603	PHASE2	UNKNOWN	Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
NCT01643408	PHASE2	COMPLETED	A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DAUNORUBICIN	4	23
MERCAPTOPURINE ANHYDROUS	4	19
PEGASPARGASE	4	9
CYCLOPHOSPHAMIDE ANHYDROUS	4	6
DOXORUBICIN	4	6
THIOGUANINE	4	6
CLOFARABINE	4	5
ASPARAGINASE ERWINIA CHRYSANTHEMI	4	4
VINDESINE	4	4
ASPARAGINASE	4	3
CYTARABINE	4	3
ETOPOSIDE PHOSPHATE	4	3
IDARUBICIN	4	3
MITOXANTRONE	4	3
NELARABINE	4	3
VINCRISTINE	4	3
BENDAMUSTINE HYDROCHLORIDE	4	2
BETAMETHASONE	4	2
BLINATUMOMAB	4	2
BORTEZOMIB	4	2
CALASPARGASE PEGOL	4	2
CLADRIBINE	4	2
DASATINIB ANHYDROUS	4	2
DEXAMETHASONE	4	2
IFOSFAMIDE	4	2
LETERMOVIR	4	2
METHOTREXATE	4	2
PONATINIB	4	2
PREDNISOLONE	4	2
TAGRAXOFUSP	4	2